Indoor Harvest Corp Announces First Quarter 2018 Improvements and Guidance

HOUSTON, May 17, 2018 (GLOBE NEWSWIRE) — Indoor Harvest Corp (“Indoor Harvest” or the “Company”) (OTCQB:INQD) is pleased to announce first quarter results for 2018, under new management after the completion of the Company’s change in focus in 2017 toward becoming a developer of personalized cannabis medicines and a provider of advanced cultivation methods and processes to the cannabis industry.

Financial Results Summary

A summary of the financial results for the quarter ended March 31, 2018, as compared to the quarter ended March 31, 2017, is as follows:

  • 88% reduction in net loss from $1,056,253 to $127,216.
  • 62% reduction in total operating expenses from $726,828 to $272,603.
  • 68% decrease in general and administrative expenses from $622,403 to $198,190.
  • 21% reduction in professional fees from $90,547 to $71,375.
  • 36% reduction in total liabilities from $1,132,644 to $727,780.
  • 41% reduction in stockholders deficit from ($999,624) to ($594,722).

Annette Knebel, the Company’s Chief Financial Officer, stated, “As can be seen by first quarter results, we have made great strides in reducing our overall operating expenses. There were however substantial expenses in the first quarter of 2017 related to the acquisition of Alamo CBD and its application to produce cannabis in Texas. We will continue to evaluate ways to cut costs and reduce operations where we can.”

In August 2017, the Company completed a reverse triangular merger with Alamo CBD, exchanging 7,584,008 shares of Indoor Harvest’s common stock, thus making Alamo CBD a wholly-owned subsidiary of the Company. Additionally, we ceased actively supporting business development of vertical farms for produce production.

Alamo CBD is a pending applicant to produce cannabis in Texas, placing 16th out of 43 applicants, under the Texas Compassionate Use Program. So far three applicants have been awarded approvals to produce cannabis under the program. The Company is a member of and is working with the Medical Cannabis Association of Texas and expects both lobbying and legislative efforts currently being undertaken to result in the program being expanded, additional permits being awarded, and new legislation being introduced in 2019 to allow for a separate permitting process to conduct cannabis research in line with the Controlled Substance Act. There is no guarantee that these efforts will result in the Company obtaining a license or permit to produce cannabis in Texas or that legislation will be adopted allowing a separate licensing or permitting process for research purposes.

In early February of 2018, Dr. Coleman and Benjamin Coleman, previous majority shareholders of Alamo CBD, voluntarily returned and canceled an aggregate of 3,280,470 common shares in order to prevent additional dilution to the shareholders during the Company’s efforts to secure new senior management, provide additional incentive equity and to form an advisory board.

“Efforts in Texas are ongoing and feedback as well as support from legislators and the medical community has been very promising,” stated Dan Weadock, Indoor Harvest’s Chief Executive Officer. “We have our foot in the door with our pending application and have put into place some really great partnerships, both in science and technology. With the world’s largest and most respected medical complex located in Houston, hosting both medical research and treatment facilities, the future of pharmaceutical development of cannabis in the state of Texas is quite promising”

Operations Summary

During the first quarter of 2018, the Company completed the following key efforts:

  • Added new senior management, including Mr. Daniel Weadock as Chief Executive Officer and Ms. Sandra Fowler as Chief Marketing Officer.
  • Formed a Scientific Advisory Board comprised of Dr. Ronald Walter, Dr. Nadia Sabeh and Mr. Damian Solomon to assist in the development of the Company’s business plan.
  • Completed initial conceptual design and engineering work to integrate the Company’s HPA technology with HVAC systems with its partner Harvest Air, LLC.
  • Entered into discussions with cannabis producers in Canada and the United States to utilize the Company’s technology and methods.

“We’ve opened up discussions with several key groups in the United States, Canada and Europe to look at ways to partner and so far the interest has been strong. We’re pursuing opportunities that will not only allow us to showcase our technology, but to establish research partnerships that will enable us to begin testing climate recipes to manipulate the phenotypic response of cannabis and testing the effects of combining certain microbe technologies with aeroponics. The Company is well positioned in what I expect will be a surge of interest in innovation, especially from those looking at the pharmaceutical potential of cannabis,” further stated Mr. Weadock.

The Company expects to begin to resume quarterly conference calls with shareholders and investors and will also schedule the Company’s annual shareholder meeting in the second half of 2018.

About Indoor Harvest Corp

Indoor Harvest Corp (OTCQB:INQD), through its brand name Indoor Harvest®, is a technology company focused on enabling the production of biopharma grade cannabis for research and development of true pharma grade personalized medicines. The Company is a pending applicant under the Texas Compassionate Use Program and is planning to develop facilities in Arizona and Colorado. We are seeking to use the relationships and technology we have developed to become a registered producer and seller under the federal Controlled Substance Act (“CSA”) of pharmaceutical grade Cannabis for research by third parties developing targeted treatment for specific medical symptoms.

Forward-Looking Statements

This release contains certain “forward-looking statements” relating to the business of Indoor Harvest and its subsidiary companies, which can be identified by the use of forward-looking terminology such as “estimates,” “believes,” “anticipates,” “intends,” expects” and similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission. These forward-looking statements are based on Indoor Harvest’s current expectations and beliefs concerning future developments and their potential effects on Indoor Harvest. There can be no assurance that future developments affecting Indoor Harvest will be those anticipated by Indoor Harvest. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the Company) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Indoor Harvest undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Contact Information

Indoor Harvest Corp
Dan Weadock, Chief Executive Officer


    March 31,
    December 31,
Current assets:                
Cash   $ 42,981     $ 35,453  
Prepaid rent           4,452  
Unused commitment fee     50,000       50,000  
Total current assets     92,981       89,905  
Furniture and equipment, net     22,014       24,623  
Security deposit     12,600       12,600  
Intangible asset, net     5,463       5,892  
Total assets   $ 133,058     $ 133,020  
Current liabilities:                
Accounts payable and accrued expenses   $ 109,574     $ 89,033  
Convertible notes payable, net of debt discount of $24,228 and
$69,541, respectively
    565,272       455,459  
Derivatives liability     25,006       554,917  
Accrued payroll     3,722       6,653  
Deferred rent     5,671       6,239  
Note payable – current portion     7,714       7,520  
Total current liabilities     716,959       1,119,821  
Long term liabilities:                
Note payable     10,821       12,823  
Total liabilities     727,780       1,132,644  
Stockholders’ deficit:                
Series A Convertible Preferred stock: $0.01 par value, 5,000,000
shares authorized; 750,000 shares issued and outstanding at both
March 31, 2018 and December 31, 2017
    7,500       7,500  
Common stock: $0.001 par value, 50,000,000 shares authorized;
23,688,240 and 25,503,678 shares issued and outstanding at March
31, 2018 and December 31, 2017, respectively
    23,971       25,502  
Additional paid-in capital     7,909,845       7,376,196  
Accumulated deficit     (8,536,038 )     (8,408,822 )
Total stockholders’ deficit     (594,722 )     (999,624 )
Total liabilities and stockholders’ deficit   $ 133,058     $ 133,020  


    For the three months ended
March 31,
    2018     2017  
Revenue   $     $  
Cost of sales            
Gross profit            
Operating expenses                
Depreciation and amortization expense   $ 3,038     $ 13,141  
Research and development           737  
Professional fees     71,375       90,547  
General and administrative expenses     198,190       622,403  
Total operating expenses     272,603       726,828  
Loss from operations     (272,603 )     (726,828 )
Other income (expense)                
Other income (expense)     4       (11,733 )
Interest expense     (17,669 )     (112,685 )
Amortization of debt discount     (80,563 )     (205,007 )
Change in fair value of embedded derivative liability     243,615        
Total other income (expense)     145,387       (329,425 )
Net loss   $ (127,216 )   $ (1,056,253 )
Net loss per common share:                
Net loss per share, basic and diluted   $ (0.01 )   $ (0.06 )
Weighted average number of common shares outstanding:                
Basic and diluted     24,649,867       16,816,214  


    Series A
Preferred Stock,
$0.01 Par Value
    Common Stock,
$0.001 Par Value
Paid in
    Accumulated     Total

    Shares     Amount     Shares     Amount     Capital     Deficit     (Deficit)  
Balances, December 31, 2017     750,000     $ 7,500       25,503,678     $ 25,502     $ 7,376,196     $ (8,408,822 )   $ (999,624 )
Common stock issued for services – related party                 285,522       285       79,788             80,073  
Convertible debt converted into common stock                 1,465,032       1,464       148,535             149,999  
Voluntary return of stock by related party                 (3,280,470 )     (3,280 )     3,280              
Derivative liability                             286,296             286,296  
Beneficial conversion feature                             15,750             15,750  
Net loss for the three months ended March 31, 2018                                   (127,216 )     (127,216 )
Balances, March 31, 2018     750,000     $ 7,500       23,973,762     $ 23,971     $ 7,909,845     $ (8,536,038 )   $ (594,722 )


    For the three months ended
March 31,
    2018     2017  
Cash flows from operating activities:                
Net loss   $ (127,216 )   $ (1,056,253 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation and amortization expense     3,038       13,141  
Amortization of debt discount     80,563       205,007  
Change in fair value of embedded derivative liability     (243,615 )      
Stock issued for services – related party     80,073       109,930  
Stock issued for services           352,000  
Change in operating liability:                
  Decrease in accounts receivable           34,853  
  Decrease in prepaid expense     4,452        
  Increase (decrease) in accounts payable and accrued expenses     20,541       (3,071 )
  Decrease in deferred rent     (568 )     (568 )
  Decrease in accrued compensation – officers     (2,931 )     (7,142 )
      Net cash used in operating activities     (185,663 )     (352,103 )
Cash flows from investing activities:                
Investment in joint venture           (250,000 )
Purchase of equipment and software           (550 )
    Net cash used in investing activities           (250,550 )
Cash flows from financing activities:                
Repayments of note payable     (1,809 )     (227,132 )
Proceeds from convertible notes payable, less offering costs and OID costs paid     195,000        
Proceeds from demand note payable, less OID costs paid           250,000  
Repayment of convertible note           (175,000 )
Issuance of common stock for cash           824,000  
    Net cash provided by financing activities     193,191       671,868  
Decrease in cash and cash equivalents     7,528       69,215  
Cash and cash equivalents at beginning of period     35,453       78,219  
Cash and cash equivalents at end of period   $ 42,981     $ 147,434  
Supplementary disclosure of cash flow information:                
Cash paid during the period for:                
Interest   $ 506     $ 682  
Income taxes   $     $  
Supplemental disclosure of non-cash investing and financing activities:                
Beneficial conversion feature   $ 15,750     $ 95,333  
Settlement of convertible note into common shares   $     $ 100,000  
Partial conversion of convertible note into common shares   $ 150,000     $  
Conversion of preferred shares into common shares   $     $ 2,500  
Derivative liability reclassified to paid-in capital   $ 286,296     $  
Voluntary return of stock by related party   $ 3,280     $  

Share this post